Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan Institutional business has unveiled Mesna Injection, 100 mg/mL, packaged in 1,000 mg/10mL multiple-dose vials.
Subscribe to our email newsletter
The product is the generic equivalent to Baxter Healthcare’s Mesnex Injection.
Mylan has begun shipping the generic drug, which has been approved by the US Food and Drug Administration.
Mesna Injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis, which had US sales of approximately $11.7m for the 12 months ending 31 December 2011, according to IMS Health.